Authors : Dasari Mercy Leona; Areboina Lavanya

Volume/Issue : Volume 9 - 2024, Issue 5 - May

Google Scholar : https://tinyurl.com/yc4rtvy8

Scribd : https://tinyurl.com/tb323yhu

DOI : https://doi.org/10.38124/ijisrt/IJISRT24MAY506

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Pharmacogenomics studies how genetics affects how drugs affect the human body. The terms genomics and pharmacology are the sources of the field's name, which represents the intersection of genetics and medicine. The discovery of the laws of heredity in 1866 marked the beginning of the area of pharmacogenetics (PGx). The FDA has established PGx testing recommendations, so whenever these 250+ drugs are being reviewed, testing should be considered. Physicians in the fields of pain management, mental health, and cardiovascular health are among those who provide PGx recommendations. Antidepressant medications offer several therapeutic options that are similar, which makes them a prime candidate for the use of PGx. It makes sense that pharmaceutical companies are hesitant to use pharmacogenomics in clinical investigations given its relative youth. Clinical trials and pharmacogenomic testing together have many advantages. Finding populations with risk factors unrelated to the medication itself may also be facilitated by pharmacogenetics. Oral anticoagulants and chemotherapy treatment regimens are now recommended based on a patient's pharmacogenetic condition. When it comes to patient dosing, pharmacogenetic techniques are gradually replacing the traditional method of depending solely on trial and error. The present therapeutic application of pharmacogenetics can also be applied to drug research and development.

Keywords : Pharmacogenetics, Single Nucleotide Polymorphisms, Adverse Drug Events, Pharmaceutical.

References :

1. Hughes D, Andersson DI. Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat Rev Genet [Internet]. 2015;16(8):459–71.
2. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature [Internet]. 2004;429(6990):464–8.
3. Pirmohamed M. Pharmacogenetics: past, present and future. Drug Discov Today [Internet]. 2011;16(19–20):852–61.
4. Pirmohamed M. Pharmacogenetics and pharmacogenomics. Br J Clin Pharmacol [Internet]. 2001;52(4):345–7.
5. Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?: Pharmacogenetics and pharmacogenomics. Clin Genet [Internet]. 1999;56(4):247–58.
6. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science [Internet]. 1999;286(5439):487–91.
7. Lemke AA, Hulick PJ, Wake DT, Wang C, Sereika AW, Yu KD, et al. Patient perspectives following pharmacogenomics results disclosure in an integrated health system. Pharmacogenomics [Internet]. 2018;19(4):321–31.
8. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther [Internet]. 2007;116(3):496–526.
9. Vitek R, Abul-Husn CR, Connolly NS. Healthcare provider education to support integration of pharmacogenomics in practice: the eMERGE Network experience. Pharmacogenomics. 2017;18(10):1013–25.
10. Lemke AA, Hutten Selkirk CG, Glaser NS, Sereika AW, Wake DT, Hulick PJ, et al. Primary care physician experiences with integrated pharmacogenomic testing in a community health system. Per Med [Internet]. 2017;14(5):389–400.
11. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med [Internet]. 2013;369(24):2283–93.
12. Mega JL, Hochholzer W, Frelinger AL 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA [Internet]. 2011;306(20):2221–8.
13. Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui C-H, Stein CM, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther [Internet]. 2019;105(5):1095–105.
14. Relling MV, McDonagh EM, Chang T, Caudle KE, McLeod HL, Haidar CE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther [Internet]. 2014;96(2):169–74.
15. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe’er I, Floratos A, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet [Internet]. 2009;41(7):816–9.
16. Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J [Internet]. 2017;17(5):395–402.
17. Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab [Internet]. 2014;15(2):209–17.
18. Dickson M, Gagnon JP. Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov [Internet]. 2004;3(5):417–29.
19. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ [Internet]. 2003;22(2):151–85.
20. Joseph T, Kusumakumary P, Chacko P, Abraham A, Radhakrishna Pillai M. Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatr Blood Cancer [Internet]. 2004;43(5):560–7.
21. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A [Internet]. 2000;97(19):10483–8.
22. Chung W-H, Chang W-C, Lee Y-S, Wu Y-Y, Yang C-H, Ho H-C, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA [Internet]. 2014;312(5):525.
23. Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet [Internet]. 2013;382(9894):790–6.
24. Syn NL, Wong AL-A, Lee S-C, Teoh H-L, Yip JWL, Seet RCS, et al. Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial. BMC Med [Internet]. 2018;16(1).
25. Behr ER, Ritchie MD, Tanaka T, Kääb S, Crawford DC, Nicoletti P, et al. Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes. PLoS One [Internet]. 2013;8(11):e78511.